SAN MARINO, Calif. — Epeius Biotechnologies Corporation announced today that the company has taken a major step toward the commercialization of its lead product with the opening of a Phase II Registration Protocol using Rexin-G for osteosarcoma in the United States. Following the accelerated approval of Rexin-G for the treatment of all solid tumors by the Bureau of Food and Drugs in the Philippines, Epeius opened a number of Phase I/II clinical trials.
FDA Approves the Opening of a Phase II Registration Protocol Using Rexin-G for Osteosarcoma
Wed, 07 Nov 2007 21:47:40 -0800 PST
by Tabitha Berg - Staff Editor
» READ FULL STORY
Related Searches: News: FDA Approval, News: Medical, News: Pharma, Newsdesk, State: California, Story Index
Related Searches: News: FDA Approval, News: Medical, News: Pharma, Newsdesk, State: California, Story Index
MMDI’s Rebound HRD Receives FDA 510(k) Clearance
Wed, 22 Aug 2007 23:45:54 -0700 PDT
by Aria Munro - Staff Editor
MINNEAPOLIS, Minn. — Minnesota Medical Development, Inc. (MMDI) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to its new Rebound HRD(TM) (Hernia Repair Device). The Rebound HRD is intended to assist in the repair and/or reinforcement of hernia or other soft tissue defects where weakness exists and where the support of a nonabsorbable material is preferred.
» READ FULL STORY
Related Searches: News: FDA Approval, News: Medical Devices, Newsdesk, State: Minnesota, Story Index
Related Searches: News: FDA Approval, News: Medical Devices, Newsdesk, State: Minnesota, Story Index